FEBS Journal · 2010 · 12 citations · 30 references
PharmacyMedicinal ChemistryMicrobiologyAntibody EngineeringDrug DesignDrug DiscoveryAntibody Specificity EngineeringAntimicrobial PeptidesEnzyme FunctionPeptide ChemistryPeptidomimetic DesignProtein DesignBeta-lactamase InhibitorsCarbapenemase EnzymesCatalytic Antibody MechanismsCombinatorial Cyclic Peptide SynthesisCyclic Peptide DesignCyclic Peptide LibrariesNovel Beta-lactamase DiscoverySynthetic Antimicrobial Peptide Design
9G4H9, a catalytic antibody displaying β-lactamase-like activity, has been developed by the anti-idiotypic approach using β-lactamase as the first antigen. Thus 9G4H9 represents the 'internal image' of β-lactamase. We selected a cyclic peptide anchored to a bacteriophage M13 library using 9G4H9 as the target. Pep90 is a cyclic heptapeptide enclosed between two cysteine residues. We showed that Pep90 could inhibit both TEM-1 β-lactamase (K(i) = 333 μm) and several penicillin-binding proteins (IC₅₀ values ranging from 6-62 μm). We determined that the tryptophan residue of Pep90 is of crucial importance for its inhibitory activity. Using Pep90 as a scaffold, we generated a new class of peptidomimetics that retained inhibitory activity towards TEM-1 β-lactamase.
30
Towards a network theory of the immune system.
Jerne Nk · PubMed · 1974 · 3.4K citations
Life Sciences, Biology, Immunology +14